secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001104659-25-087465
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics shareholders approve equity plan increase and elect directors at annual meeting
--------------------------------------------------------------------------------

- Shareholders approved Amendment No. 3 to increase shares under 2020 Stock Incentive Plan from 2.5M to 4.5M.
- All four director nominees elected: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, Jeffrey Wolf.
- Ratified BDO USA, P.C. as independent auditor for FY2025 with 3.61M votes for.
- Advisory vote on executive compensation approved; future frequency set at three years.
- Vote totals for each proposal are disclosed; broker non-votes totaled 2,212,112 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925087465/0001104659-25-087465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925087465/tm2525057d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-087465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer